RadNet (RDNT) Stock Price, News & Analysis

Company Overview

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $45.82 to $48.24
• 50-Day Range: $45.92 to $72.75
• 52-Week Range: $42.45 to $93.65
• Volume: 761,468 shs
• Average Volume: 888,181 shs
• Market Capitalization: $3.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $76.75
• Consensus Rating: Buy

RadNet Stock Analysis - MarketRank™

RadNet scored higher than 83% of companies evaluated by MarketBeat, and ranked 170th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

RadNet has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

RadNet has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -5.36%

Earnings Growth

Earnings for RadNet are expected to decrease by -5.36% in the coming year, from $0.56 to $0.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RadNet is -655.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RadNet is -655.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RadNet has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.07% of the float of RadNet has been sold short.

Short Interest Ratio / Days to Cover

RadNet has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in RadNet has recently decreased by 5.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RadNet does not currently pay a dividend.

Dividend Growth

RadNet does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.52

Percentage of Shares Shorted

8.07% of the float of RadNet has been sold short.

Short Interest Ratio / Days to Cover

RadNet has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in RadNet has recently decreased by 5.97%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.56

News Sentiment

RadNet has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for RadNet this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for RDNT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added RadNet to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, RadNet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,426,680.00 in company stock.

Percentage Held by Insiders

Only 5.12% of the stock of RadNet is held by insiders.

Percentage Held by Institutions

77.90% of the stock of RadNet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RDNT Stock Analysis - Frequently Asked Questions

How have RDNT shares performed this year?

RadNet's stock was trading at $69.84 at the start of the year. Since then, RDNT shares have decreased by 34.2% and is now trading at $45.92.
View the best growth stocks for 2025 here.

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) issued its quarterly earnings results on Thursday, February, 27th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.01. The medical research company had revenue of $477.10 million for the quarter, compared to analysts' expectations of $459.42 million. RadNet had a positive trailing twelve-month return on equity of 4.29% and a negative net margin of 0.25%.

Who are RadNet's major shareholders?

Top institutional shareholders of RadNet include Vanguard Group Inc. (10.03%), Beck Mack & Oliver LLC (4.15%), RTW Investments LP (2.67%) and Invesco Ltd. (2.34%). Insiders that own company stock include Alma Gregory Sorensen, Norman R Hames, Ranjan Jayanathan, David L Swartz, Lawrence L Levitt, Mark Stolper, David Jeffrey Katz, Cornelis Wesdorp, Michael N Murdock, Christine Nayoma Gordon and Gregory E Spurlock.
View institutional ownership trends.

How do I buy shares of RadNet?

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RadNet investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:RDNT
• CIK: 790526
• Web: www.radnet.com
• Phone: (310) 445-2800
• Fax: 310-445-2980
• Employees: 8,970
• Year Founded: 1980

Price Target and Rating

• Average Stock Price Target: $76.75
• High Stock Price Target: $88.00
• Low Stock Price Target: $65.00
• Potential Upside/Downside: +67.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.03
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 82.00
• P/E Growth: N/A
• Net Income: $3.04 million
• Net Margins: -0.25%
• Pretax Margin: 2.05%
• Return on Equity: 4.29%
• Return on Assets: 1.45%

Debt

• Debt-to-Equity Ratio: 0.89
• Current Ratio: 2.16
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: $1.83 billion
• Price / Sales: 1.86
• Cash Flow: $2.44 per share
• Price / Cash Flow: 18.81
• Book Value: $11.79 per share
• Price / Book: 3.89

Miscellaneous

• Outstanding Shares: 74,042,000
• Free Float: 70,237,000
• Market Cap: $3.40 billion
• Optionable: Optionable
• Beta: 1.85